Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features (Q91177773)
Jump to navigation
Jump to search
scientific article published on 28 August 2018
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features |
scientific article published on 28 August 2018 |
Statements
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features (English)
Anna L Godfrey
Peter J Campbell
Cathy MacLean
Georgina Buck
Julia Cook
Julie Temple
Bridget S Wilkins
Keith Wheatley
Jyoti Nangalia
Jacob Grinfeld
Mary Frances McMullin
Cecily Forsyth
Jean-Jacques Kiladjian
Claire N Harrison
United Kingdom Medical Research Council Primary Thrombocythemia-1 Study
United Kingdom National Cancer Research Institute Myeloproliferative Neoplasms Subgroup
French Intergroup of Myeloproliferative Neoplasms
and the Australasian Leukaemia and Lymphoma Group.
28 August 2018